Induction of humoral and cellular immune responses against the HIV-1 envelope protein using γ-retroviral virus-like particles
- Tea Kirkegaard1,
- Adam Wheatley5,
- Jesper Melchjorsen1,
- Shervin Bahrami2,
- Finn S Pedersen3, 4,
- Robert J Center5,
- Damian FJ Purcell5,
- Lars Ostergaard1,
- Mogens Duch3, 4 and
- Martin Tolstrup1Email author
© Kirkegaard et al; licensee BioMed Central Ltd. 2011
Received: 12 April 2011
Accepted: 1 August 2011
Published: 1 August 2011
This study evaluates the immunogenicity of the HIV envelope protein (env) in mice presented either attached to γ-retroviral virus-like-particles (VLPs), associated with cell-derived microsomes or as solubilized recombinant protein (gp160). The magnitude and polyfunctionality of the cellular immune response was enhanced when delivering HIV env in the VLP or microsome form compared to recombinant gp160. Humoral responses measured by antibody titres were comparable across the groups and low levels of antibody neutralization were observed. Lastly, we identified stronger IgG2a class switching in the two particle-delivered antigen vaccinations modalities compared to recombinant gp160.
The induction of neutralizing antibodies remains key to developing an efficient preventive HIV vaccine. The strongest evidence in support of this comes from non-human primate studies, which demonstrate that broadly neutralizing antibodies can protect from infection [1, 2]. The functional HIV envelope protein (env) complex consists of three heterodimers of the surface subunit gp120 and the transmembrane subunit gp41 arranged in trimeric spikes . Gp120 binds in a sequential manner to CD4 and to a co-receptor (in most cases either CXCR4 or CCR5) on the target cell. These interactions promote extensive conformational changes in both gp120 and gp41, which leads to fusion of the viral and target-cell membranes. For vaccination purposes antibodies raised to monomeric gp120 antigens primarily target the oligomeric interface, which is not exposed in the functional trimeric structure . Therefore, in order to elicit neutralizing antibodies with high efficacy directed towards the native forms of env, trimeric structure, ideally in a membrane-bound form should be a crucial property of env vaccine candidates for immunization.
The production and purification of soluble recombinant env proteins having a native trimeric conformation remains challenging . As an alternative, HIV env can be presented as membrane anchored trimers on virus-like particles (VLPs) [6–8]. Several studies imply that membrane-associated trimeric env can raise higher antibody titers with increased neutralization potency compared to soluble recombinant gp120 or gp160 [9, 10], and a VLP-based vaccination strategy has previously elicited some strain-specific neutralizing activity in mice and macaques .
In order to efficiently pseudotype MLV particles with HIV env, a cytoplasmic tail-truncated HIV env is required [12, 13]. This limits the retrograde trafficking of HIV env localized on the cell surface by removing endocytosis signals within the cytoplasmic tail of gp41 , which in turn enhances env virion incorporation . Importantly, several well-characterized neutralizing antibodies are equally potent in inhibiting both native as well as C-terminal truncated env .
The aim of this study was to compare the immunogenicity of env antigens delivered via γ- retroviral-like particles consisting of murine leukemia virus (MLV) gag and HIV env (termed HIV env/gag+), a purified cell fraction containing microsomes and HIV env without a viral core (termed HIV env/gag-) and recombinant gp160 (uncleaved env precursor consisting of contiguous gp120 and gp41 domains) produced in H9 cells, detergent solubilized and immuno-affinity purified .
In conclusion, these results indicate that relative to recombinant protein immunogens, γ-retroviral-based VLPs and microsome incorporated env can stimulate quantitative and qualitative improvements in T cell responses targeting HIV env. Thus, a vaccine platform using particle-delivered env trimers appears robust and immunogenic, and also holds advantages as to vector safety. The sequence similarity between γ-retroviruses and lentiviruses is very small, reducing the potential for recombination. The microsome delivery of antigen appear indistinguishable from the γ-retroviral-based VLP in terms of immunogenicity but incorporation of env was less efficient posing challenges in terms of larger scale production. Summarized, we believe these immunogenic and safety features support further investigations of particle-delivered HIV env for vaccinations against HIV.
This work was supported by grants the Danish AIDS Foundation, the Scandinavian Society of Antimicrobial Chemotherapy, Region Midtjylland Research Foundation and the Toyota Foundation Denmark. We thank Professor T. Kitamura for the GagPol construct GagPol-IRES-bsr. FluoroSpot plates were kindly enumerated by Staffan Paulie, Mabtech, Sweden.
- Johnson PR, Schnepp BC, Zhang J, et al.: Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 2009, 15:901–906.PubMedView Article
- Mascola JR, Stiegler G, VanCott TC, et al.: Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000, 6:207–210.PubMedView Article
- Zhu P, Liu J, Bess J, et al.: Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 2006, 441:847–852.PubMedView Article
- Montefiori DC, Mascola JR: Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? Curr Opin HIV AIDS 2009, 4:347–351.PubMedView Article
- Hoxie JA: Toward an antibody-based HIV-1 vaccine. Annu Rev Med 2010, 61:135–152.PubMedView Article
- Crooks ET, Moore PL, Franti M, et al.: A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology 2007, 366:245–262.PubMedView Article
- McBurney SP, Young KR, Ross TM: Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. Virology 2007, 358:334–346.PubMedView Article
- Quan FS, Sailaja G, Skountzou I, et al.: Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins. Vaccine 2007, 25:3841–3850.PubMedView Article
- Buonaguro L, Visciano ML, Tornesello ML, Tagliamonte M, Biryahwaho B, Buonaguro FM: Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J Virol 2005, 79:7059–7067.PubMedView Article
- Hammonds J, Chen X, Fouts T, DeVico A, Montefiori D, Spearman P: Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization. J Virol 2005, 79:14804–14814.PubMedView Article
- Bellier B, Huret C, Miyalou M, et al.: DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies. Vaccine 2009, 27:5772–5780.PubMedView Article
- Mammano F, Salvatori F, Indraccolo S, De Rossi A, Chieco-Bianchi L, Göttlinger HG: Truncation of the human immunodeficiency virus type 1 envelope glycoprotein allows efficient pseudotyping of Moloney murine leukemia virus particles and gene transfer into CD4+ cells. J Virol 1997, 71:3341–3345.PubMed
- Schnierle BS, Stitz J, Bosch V, et al.: Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells. Proc Natl Acad Sci USA 1997, 94:8640–8645.PubMedView Article
- Byland R, Vance PJ, Hoxie JA, Marsh M: A conserved dileucine motif mediates clathrin and AP-2-dependent endocytosis of the HIV-1 envelope protein. Mol Biol Cell 2007, 18:414–425.PubMedView Article
- Devitt G, Emerson V, Holtkotte D, Pfeiffer T, Pisch T, Bosch V: Incorporation of chimeric HIV-SIV-Env and modified HIV-Env proteins into HIV pseudovirions. Virology 2007, 361:465–471.PubMedView Article
- Kim YB, Lee MK, Han DP, Cho MW: Development of a safe and rapid neutralization assay using murine leukemia virus pseudotyped with HIV type 1 envelope glycoprotein lacking the cytoplasmic domain. AIDS Res Hum Retroviruses 2001, 17:1715–1724.PubMedView Article
- Kalyanaraman VS, Rodriguez V, Veronese F, et al.: Characterization of the secreted, native gp120 and gp160 of the human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1990, 6:371–380.PubMedView Article
- Morita S, Kojima T, Kitamura T: Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther 2000, 7:1063–1066.PubMedView Article
- Tolstrup M, Selzer-Plön J, Laursen AL, et al.: Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137 K). AIDS 2007, 21:519–521.PubMedView Article
- Cantin R, Diou J, Bélanger D, Tremblay AM, Gilbert C: Discrimination between exosomes and HIV-1: purification of both vesicles from cell-free supernatants. J Immunol Methods 2008, 338:21–30.PubMedView Article
- Center RJ, Wheatley AK, Campbell SM, et al.: Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. Vaccine 2009, 27:6605–6612.PubMedView Article
- Leclerc C, Dériaud E, Rojas M, Whalen RG: The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. Cell Immunol 1997, 179:97–106.PubMedView Article
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.